Innovating Works

Impentri

Financiado
First effective pharmacotherapy for ARDS to lower mortality and improve quality...
First effective pharmacotherapy for ARDS to lower mortality and improve quality of life of patients. Acute Respiratory Distress syndrome (ARDS) is a life threatening condition that affects 3 million people world-wide. With regards to the current coronavirus pandemic, ARDS is the immediate cause of death for patients suffering fro... Acute Respiratory Distress syndrome (ARDS) is a life threatening condition that affects 3 million people world-wide. With regards to the current coronavirus pandemic, ARDS is the immediate cause of death for patients suffering from this infection. 40% of the patients that suffer from the condition succumb to it and among the ones that survive, most of them face long-term physical and mental illness. The unreliable, costly, prolonged treatment options currently available are responsible for the high mortality observed in the condition. The treatments offer only relief from symptoms and manage the condition but are not curative. Exvastat is developing impentri as a reliable and effective pharmacotherapy for ARDS as it targets the cause and trigger of the mortality associated with the condition. It is an intravenous formulation of widely-used chemotherapeutic drug, Imatinib which has shown promising results in-vitro and clinical reports in ARDS like conditions. Being a repurposed drug, Impentri has the advantage of reaching human trials earlier than other drugs. With EIC funds Exvastat plans to register and successfully finish 50% of the PhaseII trials in ARDS patients. This would provide an opening for the drug to successfully finish further trials and its orphan drug status would guarantee early market entry. With Impentri Exvastat wants to lower mortality and provide better quality of life to patients suffering from ARDS ver más
30/09/2022
EXVASTAT LTD
2M€
Duración del proyecto: 19 meses Fecha Inicio: 2021-02-18
Fecha Fin: 2022-09-30

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2022-09-30
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
EIC-SMEInst-2018-2020: SME instrument
Cerrada hace 6 años
Presupuesto El presupuesto total del proyecto asciende a 2M€
Líder del proyecto
EXVASTAT LTD No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5